The Stocks Most Impacted by the 2020 US Presidential Election
Which Stocks Are Most Affected by the 2020 US Presidential Election?
As we approach the 2020 election, you must be wondering: how will the elected candidate impact the stock market and certain key stocks in particular?
Experience tells us that it is a challenge to predict anything concrete about the impact of the upcoming election on specific stocks, and the specific stocks that thrive or struggle are often counterintuitive. For example, traders feared that the Obama Administration’s focus on gun control would hurt firearm stocks or that President Trump’s more “status quo” plan for healthcare would benefit medical stocks, at least relative to Hillary Clinton’s more dramatic proposal to overhaul the nation’s entire healthcare system. In both of those cases, the “logical” outcome was wrong: firearm manufacturers crushed the broader stock market throughout Obama’s presidency, whereas the healthcare sector is essentially performing in-line with the broader market since Election Day 2016:
Source: TradingView, GAIN Capital
Generally speaking, volatility in the S&P 500 is typically higher in election years compared to non-election years as traders weigh the ever-fluctuating polls and try to predict the political impact on their portfolios. According to JP Morgan, markets tend to react well to the election of a Republican president in the immediate aftermath of election day. Why is this the case? Generally speaking, Republican party policies are broadly thought to be more market friendly, though that reaction isn’t guaranteed; we don’t have to look back too far to see the stock market’s short-lived overnight dive as traders came to terms with President Trump’s surprise election night victory in 2016.
When it comes to this year’s election, economic volatility from policies will be most dramatic at a sector and industry level, rather than for the broad economy. Heading into Election Night 2020, there are several sectors that may see dramatic moves based on the results:
1) Healthcare: With presumptive Democratic nominee Joe Biden incorporating elements of former rival Bernie Sanders’ more substantial health care reform proposal (though crucially, not endorsing a full “Medicare for All” style overhaul) , the healthcare sector is poised for large policy-related moves. Despite his bluster to the contrary, President Trump has done little to further regulate big pharma firms in particular, so stocks like Johnson and Johnson (JNJ), Roche (ROG), Novartis (NVS), Merck (MRK), Abott Laboratories (ABT) and Amgen (AMGN) could benefit from a potential reelection of Donald Trump.
2) Energy: Democrats remain largely unified around the risks posed by climate change, and are therefore more likely to enact regulations on the fossil fuel industry and policies that promote clean energy adoption. As with Big Pharma names, another Trump victory could boost traditional energy conglomerates like Exxon Mobil (XOM), Royal Dutch Shell (RDS), Chevron (CVX), Total (TOT) and BP (BP).
3) Technology: Politicians on both sides of the aisle are growing increasingly antagonistic to the mega-cap technology firms that continue gobble up market share and embed themselves more deeply into every aspect of modern society. It’s difficult to handicap which party would be more likely to pursue aggressive antitrust actions against companies like Apple (AAPL), Amazon (AMZN), Facebook (FB), Alphabet (GOOG), or Netflix (NFLX), but either way, traders of all stripes will be watching this space closely. For what it’s worth, AAPL, AMZN, and NFLX are all up by more than 300% since the 2016 election, so bulls will definitely be hoping for more of the same in the coming four years!
4) Media: In another example of a counterintuitive outcome, media stocks have thrived despite (most) being labeled “fake news” by the current President. Stocks like AT&T (T), Twenty-First Century Fox (FOX), CBS (CBS) and Comcast (CMCSA) have all benefited from the population focusing more on current developments. These types of companies may struggle if Joe Biden wins and we see a “quieter” Commander-in-Chief over the next four years.
5) Marijuana: Relative to some of the more liberal Democratic candidates, Biden is seemingly lukewarm toward recreational marijuana, but the prospects of full legalization are nonetheless better under Biden than Trump, especially if the House of Representatives and/or Senate is also under Democratic control. In that case, stocks like Canopy Growth (CGC), GW Pharmaceuticals (GWPH), Curaleaf (CURL), Cronos Group (CRON), and Aurora Cannabis (ACB) could catch a bid, though the risk of a “buy the rumor, sell the news” event on either the election or potential signing of a federal legalization bill is possible.
As we noted, none of these situations are guaranteed to play out as expected, but policy risks are clearly elevated in both directions for the stocks highlighted above. While the drama of a presidential election is almost tailor-made for market volatility and trader overreactions, readers should ultimately watch how specific policies will impact certain sectors and companies to identify the strongest trading opportunities.
As you prepare to weather the coming storm, feel secure knowing City Index has a proven record of strength, security, and stability. Contact us today for more information on how to trade through the election and beyond with professional support.
StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.
No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.
For further details see our full non-independent research disclaimer and quarterly summary.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. CFD and Forex Trading are leveraged products and your capital is at risk. They may not be suitable for everyone. Please ensure you fully understand the risks involved by reading our full risk warning.
City Index is a trading name of StoneX Financial Ltd. Head and Registered Office: 1st Floor, Moor House, 120 London Wall, London, EC2Y 5ET. StoneX Financial Ltd is a company registered in England and Wales, number: 05616586. Authorised and regulated by the Financial Conduct Authority. FCA Register Number: 446717.
City Index is a trademark of StoneX Financial Ltd.
The information on this website is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement.
© City Index 2024